0001209191-20-065499.txt : 20201230
0001209191-20-065499.hdr.sgml : 20201230
20201230160027
ACCESSION NUMBER: 0001209191-20-065499
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201228
FILED AS OF DATE: 20201230
DATE AS OF CHANGE: 20201230
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: King Rachel K.
CENTRAL INDEX KEY: 0001589712
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36177
FILM NUMBER: 201425867
MAIL ADDRESS:
STREET 1: C/O GLYCOMIMETICS, INC.
STREET 2: 401 PROFESSIONAL DRIVE, SUITE 250
CITY: GAITHERSBURG
STATE: MD
ZIP: 20879
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GLYCOMIMETICS INC
CENTRAL INDEX KEY: 0001253689
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9708 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 240-243-1201
MAIL ADDRESS:
STREET 1: 9708 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-28
0
0001253689
GLYCOMIMETICS INC
GLYC
0001589712
King Rachel K.
C/O GLYCOMIMETICS, INC.
9708 MEDICAL CENTER DRIVE
ROCKVILLE
MD
20850
1
1
0
0
President, CEO
Common Stock
2020-12-28
4
M
0
130821
1.12
A
440240
D
Common Stock
2020-12-28
4
S
0
84176
3.91
D
356064
D
Common Stock
129401
I
By trusts
Common Stock
45741
I
By spouse
Employee Stock Option (right to buy)
1.12
2020-12-28
4
M
0
130821
0.00
D
2021-01-04
Common Stock
130821
0
D
This option exercise and subsequent sales were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on August 4, 2020.
This total includes 2,275 shares previously held by The Rachel K. King 2016 GRAT that were transferred to the Reporting Person on January 10, 2020 and are now owned directly by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.85 to $4.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
This total excludes the 2,275 shares transferred to the Reporting Person as described in footnote (2) above.
These shares are held by family trusts, for which Ms. King serves as trustee, as follows: 1,741 shares are held by The Connor A. King 1988 Trust, 1,741 shares are held by The Langley C. King 1990 Trust, 8,796 shares are held by the 1995 Connor A. King Trust, 8,796 shares are held by the 1995 Langley C. King Trust, 23,301 shares are held by The Connor King 2013 GRAT, 23,301 shares are held by The Langley C. King 2013 GRAT and 61,725 shares are held by The Rachel K. King 2016 GRAT.
The shares underlying this option are fully vested and exercisable.
/s/ Brian F. Leaf, attorney-in-fact
2020-12-30